Skip to main content

Table 1 Baseline characteristics of healthy controls and IPF patients

From: Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis – a potential biomarker role for LysoPC

  Pilot study   Validation study  
  Healthy IPF Healthy IPF
Subjects (male %) 10 (90) 10 (90) 10 (60) 11 (82)
Age (years) 68.7 ± 7.9 67.8 ± 8.6 32.4 ± 15.3 66.1 ± 8.6
BMI kg/m2 28.9 ± 5.1 26.9 ± 3.6 22.6 ± 2.7 26.3 ± 4.3
BMI ≥ 25 kg/m2 7 5 2 6
Diabetes mellitus type 2 (n) 1 2 0 3
Hypertension 5 5 0 3
Lung function
 FVC, L 4.1 ± 0.4 2.4 ± 0.5 4.5 ± 1.0 2.4 ± 0.6
 FVC (% predicted) 114.6 ± 8.5 65.1 ± 11.3 94.0 ± 10.3 63.1 ± 14.3
 DLCO (% predicted) 129.6 ± 31.1 43 ± 15.0 87.8 ± 11.3 44.6 ± 14.6
 GAP Stage (I-III) I - II I- II
Smoking status
 Current Smokers n (median pack years ± SD) 0 0 5 (8.2 ± 14.5) 0
 Former Smokers n (median pack years ± SD) 8 (5.5 ± 5.7) 8 (25.4 ± 15.2) 0 8 (13.9 ± 13.3)
Antifibrotic therapy
 Pirfenidone n (%) 6 (60) 6 (54.5)
 Nintedanib n (%) 3 (30) 4 (36.4)
 No antifibrotics n (%) 1 (10) 1 (9.1)
  1. FVC Forced vital capacity, DLCO Diffusing capacity of the lung for carbon monoxide, BMI Body Mass Index